Pacira BioSciences (PCRX) Depreciation and Depletion (2011 - 2026)

Pacira BioSciences' Depreciation and Depletion history runs 16 years deep, the most recent figure standing at $7.0 million for Q1 2026.

• On a quarterly basis, Depreciation and Depletion rose 2.94% year-over-year to $7.0 million in Q1 2026; TTM through Mar 2026 was $33.9 million, a 40.08% increase from a year earlier, with the FY2025 full-year figure at $33.7 million, up 56.74% from the prior year.
• Depreciation and Depletion was little changed at $7.0 million in Q1 2026 per PCRX's latest filing, from $7.0 million in the prior quarter.
• Across five years, Depreciation and Depletion topped out at $16.2 million in Q4 2022 and bottomed at $4.1 million in Q3 2023.
• The 5-year median for Depreciation and Depletion is $6.0 million (2024), against an average of $6.7 million.
• Across the five-year window, Depreciation and Depletion jumped 200.0% in 2022 and slumped 74.07% in 2023, its largest moves.
• Year by year, Depreciation and Depletion stood at $16.2 million in 2022, then slumped by 74.07% to $4.2 million in 2023, then jumped by 64.29% to $6.9 million in 2024, then gained by 1.45% to $7.0 million in 2025, then changed by 0.0% to $7.0 million in 2026.
• Per Business Quant, the three latest PCRX Depreciation and Depletion figures stand at $7.0 million (Q1 2026), $7.0 million (Q4 2025), and $6.9 million (Q3 2025).